Published in EMBO J on December 17, 2001
Trial of Oral Valproic Acid for Retinitis Pigmentosa (VPA) | NCT01233609
Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy (EDIBLE) | NCT02261753
Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J (2003) 11.27
Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci U S A (2004) 3.60
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol (2005) 3.05
HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature (2011) 3.01
Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci (2009) 2.95
Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res (2012) 2.83
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci U S A (2011) 2.80
Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest (2003) 2.76
The promise and peril of chemical probes. Nat Chem Biol (2015) 2.64
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res (2011) 2.54
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics (2010) 2.26
Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev (2006) 2.10
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A (2004) 2.04
A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev (2009) 1.98
Isoform-selective histone deacetylase inhibitors. Chem Soc Rev (2008) 1.72
On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res (2002) 1.69
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology (2011) 1.66
Neurons derived from transplanted neural stem cells restore disrupted neuronal circuitry in a mouse model of spinal cord injury. J Clin Invest (2010) 1.62
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol (2009) 1.58
Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci (2008) 1.58
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer (2007) 1.52
Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 complex. EMBO J (2003) 1.48
Demethylating agents in myeloid malignancies. Curr Opin Oncol (2008) 1.48
Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors. Mol Cell Biol (2008) 1.46
Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther (2010) 1.45
Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience (2008) 1.42
Histone deacetylase inhibition enhances tissue plasminogen activator release capacity in atherosclerotic man. PLoS One (2015) 1.41
A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer (2017) 1.40
The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmacology (2012) 1.40
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol (2008) 1.38
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci (Landmark Ed) (2012) 1.37
Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One (2010) 1.36
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension (2010) 1.35
Generation of neural progenitor cells by chemical cocktails and hypoxia. Cell Res (2014) 1.30
FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1. J Biol Chem (2010) 1.29
Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem (2009) 1.28
Developmental neuropathology of environmental agents. Annu Rev Pharmacol Toxicol (2004) 1.28
Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep (2008) 1.27
Histone deacetylase 2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts. Haematologica (2010) 1.25
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol (2009) 1.24
Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol (2007) 1.23
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood (2006) 1.22
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One (2013) 1.21
Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Mol Pain (2010) 1.19
Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer (2005) 1.19
Regulation of mammalian epithelial differentiation and intestine development by class I histone deacetylases. Mol Cell Biol (2004) 1.19
Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells (2014) 1.19
SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome (2011) 1.17
Derivation of human induced pluripotent stem cells for cardiovascular disease modeling. Circ Res (2011) 1.17
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J (2004) 1.16
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int (2006) 1.15
Direct transcriptional reprogramming of adult cells to embryonic nephron progenitors. J Am Soc Nephrol (2013) 1.14
Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem (2010) 1.14
Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacology (2009) 1.12
The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer (2008) 1.12
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res (2010) 1.11
Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin. ACS Med Chem Lett (2010) 1.11
Histone deacetylases control neurogenesis in embryonic brain by inhibition of BMP2/4 signaling. PLoS One (2008) 1.10
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol (2012) 1.09
Liver sinusoidal endothelial cells are a site of murine cytomegalovirus latency and reactivation. J Virol (2009) 1.08
Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology (2009) 1.08
Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol (2011) 1.08
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer (2014) 1.08
The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology (2010) 1.07
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discov Today (2009) 1.05
Teratogenic effects of antiepileptic drugs. Expert Rev Neurother (2010) 1.05
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer (2009) 1.05
High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer (2009) 1.04
In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med (2002) 1.04
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood (2014) 1.03
Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem (2011) 1.03
Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proc Natl Acad Sci U S A (2005) 1.02
Targeting voltage-gated calcium channels in neurological and psychiatric diseases. Nat Rev Drug Discov (2015) 1.02
Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res (2010) 1.01
Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer (2014) 1.01
Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. PLoS One (2013) 1.01
Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. Am J Pathol (2009) 1.00
From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol (2014) 1.00
Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol (2014) 1.00
Fat circadian biology. J Appl Physiol (1985) (2009) 1.00
Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol (2011) 1.00
Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci. J Biol Chem (2010) 1.00
Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology (2012) 0.99
Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res (2010) 0.99
miR-206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of HDAC4. PLoS One (2013) 0.99
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med (2013) 0.98
Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem (2008) 0.98
Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol (2015) 0.98
Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys (2010) 0.98
Prospective influences of circadian clocks in adipose tissue and metabolism. Nat Rev Endocrinol (2010) 0.97
High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem (2011) 0.97
The language of covalent histone modifications. Nature (2000) 44.92
The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev (2000) 11.65
Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (1995) 11.53
A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature (1995) 11.18
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (1997) 9.71
Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (1997) 8.99
Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (1997) 7.66
Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell (1997) 7.64
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 7.47
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem (2001) 6.85
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (1994) 6.46
Roles of PPARs in health and disease. Nature (2000) 5.87
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature (1990) 5.50
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (2000) 5.21
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 5.12
Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev (1999) 4.92
The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr (1996) 4.62
Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays (1995) 4.43
Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A (1992) 4.38
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A (1998) 3.59
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol (1998) 3.06
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet (1998) 2.97
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst (1998) 2.64
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol (2000) 2.07
The fetal valproate syndrome. Am J Med Genet (1984) 2.04
Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell (2000) 2.02
Histone deacetylase as a therapeutic target. Trends Endocrinol Metab (2001) 1.83
The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res (1998) 1.82
Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol (1999) 1.80
Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol (1991) 1.48
Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene (2001) 1.47
Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res (2001) 1.33
Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science (1987) 1.18
A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Hum Mol Genet (2000) 1.14
Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res (1998) 1.06
Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology (1985) 1.04
Hematopoietic cytokine-dependent differentiation to eosinophils and neutrophils in a newly established acute promyelocytic leukemia cell line with t(15;17). Exp Hematol (1998) 1.00
Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem Suppl (1995) 0.98
Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives. Mol Pharmacol (2001) 0.98
Enhancement of peroxisomal beta-oxidation in the liver of rats and mice treated with valproic acid. Biochem Pharmacol (1985) 0.93
New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta). Toxicol Appl Pharmacol (1999) 0.90
Asymmetric synthesis and teratogenic activity of (R)- and (S)-2-ethylhexanoic acid, a metabolite of the plasticizer di-(2-ethylhexyl)phthalate. Life Sci (1990) 0.86
Enantioselectivity in the induction of peroxisome proliferation by 2-ethylhexanoic acid. Chirality (1992) 0.86
Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (1995) 11.53
A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell (1996) 11.02
The tripartite motif family identifies cell compartments. EMBO J (2001) 9.64
The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature (1999) 7.85
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature (1992) 5.47
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science (1993) 3.89
High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res (1998) 3.56
A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 3.20
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
Binding specificity and in vivo targets of the EH domain, a novel protein-protein interaction module. Genes Dev (1997) 3.01
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 2.86
The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene (1995) 2.80
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst (1998) 2.75
Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood (1997) 2.72
Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene (2001) 2.67
Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J (1997) 2.62
The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev (1998) 2.58
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Frequent interspecific genetic exchange between commensal Neisseriae and Neisseria meningitidis. Mol Microbiol (2000) 2.52
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med (1994) 2.50
Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A (1997) 2.47
Numb is an endocytic protein. J Cell Biol (2000) 2.39
ALK+ lymphoma: clinico-pathological findings and outcome. Blood (1999) 2.38
Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. Oncogene (1994) 2.27
Signal-specific co-activator domain requirements for Pit-1 activation. Nature (1998) 2.22
T-cell receptor gene rearrangements as markers of lineage and clonality in T-cell neoplasms. Proc Natl Acad Sci U S A (1985) 2.10
Acute promyelocytic leukemia: from genetics to treatment. Blood (1994) 2.09
Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A (1986) 2.09
Upregulation of 78-kDa glucose-regulated protein in macrophages in peripheral joints of active ankylosing spondylitis. Scand J Rheumatol (2008) 2.06
Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell (2000) 2.02
eps15 and eps15R are essential components of the endocytic pathway. Cancer Res (1997) 1.99
Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc. Nature (1994) 1.97
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J (1994) 1.94
Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases. Proc Natl Acad Sci U S A (1992) 1.93
Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A (1991) 1.90
A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate Eps15 and conserved in evolution. Proc Natl Acad Sci U S A (1995) 1.87
Histone deacetylase as a therapeutic target. Trends Endocrinol Metab (2001) 1.83
Evolution of Shc functions from nematode to human. Curr Opin Genet Dev (2000) 1.80
Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene (2011) 1.79
Lymphoid tumors displaying rearrangements of both immunoglobulin and T cell receptor genes. J Exp Med (1985) 1.79
P-Lim, a LIM homeodomain factor, is expressed during pituitary organ and cell commitment and synergizes with Pit-1. Proc Natl Acad Sci U S A (1995) 1.77
Not all Shc's roads lead to Ras. Trends Biochem Sci (1996) 1.74
The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol (1998) 1.69
Extranodal lymphomas associated with hepatitis C virus infection. Am J Clin Pathol (1998) 1.66
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol (1998) 1.64
Genomic instability in induced stem cells. Cell Death Differ (2011) 1.63
Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith--Lemli--Opitz syndrome. Hum Mol Genet (2001) 1.60
Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis. J Exp Med (1986) 1.60
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia (2006) 1.60
Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene (1992) 1.59
Amplification of the c-myb oncogene in a case of human acute myelogenous leukemia. Science (1984) 1.56
VDR-Alien: a novel, DNA-selective vitamin D(3) receptor-corepressor partnership. FASEB J (2000) 1.52
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer (2007) 1.52
Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood (1999) 1.50
A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1999) 1.50
Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia (2003) 1.49
Primary effusion Burkitt's lymphoma with t(8;22) in a patient with hepatitis C virus-related cirrhosis. Hum Pathol (1997) 1.48
Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene (2001) 1.47
Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia (2002) 1.47
Penetration of benzene, toluene and xylenes contained in gasolines through human abdominal skin in vitro. Toxicol In Vitro (2006) 1.47
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med (1990) 1.47
Mapping of the molecular determinants involved in the interaction between eps15 and AP-2. Cancer Res (1997) 1.46
Shc products are substrates of erbB-2 kinase. Oncogene (1993) 1.46
Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood (1998) 1.45
Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol (2001) 1.43
Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol (1999) 1.40
Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia (2002) 1.39
Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem (2000) 1.38
Prolonged suppression of myeloid progenitor cell numbers after stopping interferon treatment for CML may necessitate delay in harvesting marrow cells for autografting. Bone Marrow Transplant (1990) 1.38
Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant (1990) 1.38
Eps15R is a tyrosine kinase substrate with characteristics of a docking protein possibly involved in coated pits-mediated internalization. J Biol Chem (1998) 1.38
The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene (1995) 1.38
Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene (2010) 1.38
Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob Agents Chemother (2001) 1.37
Recognition specificity of individual EH domains of mammals and yeast. EMBO J (1998) 1.36